人参皂苷Rg3治疗肥胖诱导的2型糖尿病研究进展  

Research Progress of Ginsenoside Rg3 in Treatment of Obesity-Induced Type 2 Diabetes Mellitus

作　　者：徐杰 董金香[1] 王蓓 邱智东[1] 姚帆 XU Jie;DONG Jinxiang;WANG Bei;QIU Zhidong;YAO Fan(School of Pharmaceutical Sciences Changchun University of Chinese Medicine,Changchun 130117,Jilin,China)

机构地区：[1]长春中医药大学药学院,吉林长春130117

出　　处：《中华中医药学刊》2021年第7期102-106,共5页Chinese Archives of Traditional Chinese Medicine

基　　金：国家自然科学基金(81803796);吉林省科技发展计划(20190103083J);吉林省中医药管理局中医药科技项目(2018029);吉林省青年人才托举工程项目(2019-2010年)。

摘　　要：2型糖尿病(T2DM)是临床上常见的慢性疾病,胰岛素抵抗(IR)是其发病的早期特征,而肥胖是其诱因之一。因此,通过改善肥胖及其诱导的胰岛素抵抗对治疗T2DM有一定意义。人参皂苷Rg3为人参主要有效成分,可通过调节脂质代谢、降低炎症反应、调节肠道菌群等途径治疗T2DM,且新剂型的应用可能会使药物发挥更好的疗效。通过阐明肥胖与IR之间的关系,并对不同剂型的人参皂苷Rg3改善T2DM的相关研究进行综述,以期为T2DM的治疗提供新思路和新方法,并为人参皂苷Rg3的应用提供新途径。Type 2 diabetes mellitus(T2 DM) is a common chronic disease in clinic. Insulin resistance(IR) is the early feature of its onset, and obesity is one of its causes. Therefore, it is necessary to treat T2 DM by improving obesity and T2 DM-induced insulin resistance. Ginsenoside Rg3, the main active component of ginseng, can be used to treat T2 DM by regulating lipid metabolism, reducing inflammatory response, and regulating intestinal flora, etc. And ginsenoside Rg3 might be more effective in new dosage form. In this paper, it clarified the relationship between obesity and IR, and relevant studies on the improvement of T2 DM by ginsenoside Rg3 in different dosage forms were reviewed in order to provide new ideas and methods for the treatment of T2 DM and new approaches for the application of ginsenoside Rg3.

关 键 词：肥胖 胰岛素抵抗 2型糖尿病 人参皂苷RG3 新剂型 

分 类 号：R259.871[医药卫生—中西医结合]